Sirolimus, a drug used to prevent organ rejection in renal transplants and suggested for COVID-19 also in [25], was identified in both network analyses, due to its inhibitory effect on MTOR, whereas baricitinib and tofacitinib were identified only in the MOI 0.01 network analysis, due to their inhibitory action on JAK2. Here, JAK2 is linked to COVID-19.